Catalyst Crew Technologies Corp. (OTC: CCTC) announced the assignment of three Venezuelan patents to its wholly-owned subsidiary, Inversiones Long 33, C.A., as part of a broader strategy to align intellectual property with its operating structure. The patents, previously held by CEO Dr. Kevin Rodan Levy, cover proprietary technologies CardioAI, PulmoAI, and NeuroAI, which are designed for healthcare analytics, predictive modeling, and clinical decision support.
The company believes consolidating IP at the operating level enhances strategic flexibility, supports regulatory alignment, and may facilitate future partnerships, licensing opportunities, and regional expansion. Catalyst Crew also intends to pursue expanded IP protection in additional jurisdictions worldwide to support long-term platform development and international deployment.
“Aligning our intellectual property within our operating structure is an important step as we continue building our platform,” said Dr. Kevin Rodan Levy, CEO. “Establishing a clear foundation around our core technologies allows us to move forward with development, partnerships, and, where appropriate, broader intellectual property protection strategies across additional markets.”
The company continues advancing its digital health and AI platform, focusing on scalable healthcare solutions including telehealth infrastructure, remote patient monitoring, and advanced analytics to improve access, efficiency, and care coordination. For more information, visit https://catalystcrewai.com or review SEC filings at www.sec.gov.
This move underscores Catalyst Crew’s transition into an AI-driven healthcare technology company targeting emerging markets, with an initial emphasis on Latin America. The company is building an integrated platform through technology development, strategic partnerships, and targeted acquisitions to address growing demand for modernized healthcare delivery systems.
